Associations between lifetime classic psychedelic use and cardiometabolic diseases
Scientific Reports – July 13, 2021
Source: OpenAlex
Summary
Lifetime classic psychedelic use correlates with significantly better cardiovascular health. Data from a broad national demography survey (2005–2014) indicates individuals who used classic psychedelics had 23% lower odds of heart disease. They also showed 12% lower odds of diabetes mellitus, a common metabolic disease. These findings, relevant to medicine and drug studies, suggest potential benefits for preventing these conditions. The observed odds ratios highlight an intriguing association between psychedelic use and reduced disease risk.
Abstract
Abstract The objective of the current study was to investigate the associations between lifetime classic psychedelic use and cardiometabolic diseases. Using data from the National Survey on Drug Use and Health (2005–2014), the present study examined the associations between lifetime classic psychedelic use and two types of cardiometabolic disease: heart disease and diabetes. Respondents who reported having tried a classic psychedelic at least once in their lifetime had lower odds of heart disease in the past year (adjusted odds ratio (aOR) = 0.77 (0.65–0.92), p = .006) and lower odds of diabetes in the past year (adjusted odds ratio (aOR) = 0.88 (0.78–0.99), p = .036). Classic psychedelic use might be beneficial for cardiometabolic health, but more research is needed to investigate potential causal pathways of classic psychedelics on cardiometabolic diseases.